arrow
T

Thomas Schmelter

Bayer AG
H指数:24
被引数:4,075

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Intravitreal Aflibercept 8 mg for Diabetic Macular Edema: 96-Week Results from the Randomized Phase 2/3 PHOTON Trial

玻璃体内注射Aflibercept 8 mg治疗糖尿病黄斑水肿:随机II/III期PHOTON试验96周结果

2025-11-100
OAAI
Intravitreal Aflibercept 8 mg in Neovascular Age-related Macular Degeneration: 96-Week Results from the Randomized Phase 3 PULSAR Trial

玻璃体内注射Aflibercept 8 mg治疗新生血管性年龄相关性黄斑变性:来自随机III期PULSAR试验96周的结果

2025-08-260
PREAI
Intravitreal aflibercept 8 mg in diabetic macular oedema (PHOTON): 48-week results from a randomised, double-masked, non-inferiority, phase 2/3 trial
LANCET
IF88.5
2024-03-019
PRE
Intravitreal aflibercept 8 mg in neovascular age-related macular degeneration (PULSAR): 48-week results from a randomised, double-masked, non-inferiority, phase 3 trial
LANCET
IF88.5
2024-03-0124
PRE
Effect of finerenone on the occurrence of vision-threatening complications in patients with non-proliferative diabetic retinopathy: Pooled analysis of two studies using routine ophthalmological examinations from clinical trial participants (ReFineDR/DeFineDR)

非增殖性糖尿病性视网膜病变患者中finerenone对视力威胁并发症发生的影响: 使用临床试验参与者的常规眼科检查对两项研究的汇总分析 (ReFineDR/DeFineDR)

2022-11-2913
OAAI
Intravitreal Aflibercept for Diabetic Macular Edema 148-Week Results from the VISTA and VIVID Studies
2016-11-01326
PREAI
Intravitreal Aflibercept for Diabetic Macular Edema 100-Week Results From the VISTA and VIVID Studies
2015-10-01438
PREAI
Intravitreal Aflibercept for Diabetic Macular Edema
2014-11-01641
OAAI